EBV infection is one of the life-threatening clinical complications in patients who underwent haploidentical hematopoietic stem cell transplantation (haploHSCT). Although immune recovery is recognized to be crucial for decreasing subsequent morbidity of infections, the link between T-cell recovery and EBV infection after haploHSCT remains elusive. We recently compared the influences of different doses of antithymocyte globulin conditioning on the T-cell reconstitution post haploHSCT and suggested that CD4
INTRODUCTION
Haploidentical hematopoietic stem cell transplantation (haploHSCT) is increasingly used as a curative therapy for patients with hematological malignancies, especially for those who lack an HLA-matched donor. Following the development of graft engineering and conditioning regimens, general outcome of haploHSCT recipients has improved significantly. [1] [2] [3] However, further success of haploHSCT is limited by the severe complications mainly attributed to the impaired immune system. EBV reactivation and its related diseases are frequent events with a high mortality after haploHSCT. 4, 5 EBV is a human γ-herpes virus that infects 490% of the world's population. In healthy persons, the proliferation of primary and latent EBV-infected cells are controlled by functional T lymphocytes. However, immunocompromised recipients after haploHSCT are vulnerable to the EBV infection. We previously reported that 1-year cumulative incidences of EBV reactivation and post-transplantation lymphoproliferative disorder after haploHSCT were 13.7% and 3%, respectively. 6, 7 Although CD20-specific monoclonal antibody rituximab has been routinely used for EBV-DNAemia, the probable 2-year overall survival of haploHSCT recipients with post-transplantation lymphoproliferative disorder was 42.8%. 7 It has been recognized that reconstitution of functional immune cells are important for preventing post-HSCT complications due to viral infections, in both children and adults. 8, 9 In terms of the association with EBV reactivation after allogeneic HSCT, researchers have rather focused on the B-cell reconstitution, as EBV generally induces post-transplantation lymphoproliferative disorder. 10 Some studies evaluated the reconstitution of EBVspecific CD8 + T lymphocytes in the cases of EBV reactivation, [11] [12] [13] however, EBV reactivations usually occurred within the first 3 months after HSCT by that time EBV-CD8 + T lymphocytes had not yet become detectable in most recipients. 11 It was reported that innate lymphocytes reconstituted faster than adaptive T cells after allogeneic HSCT.
14 Nevertheless, the recovery characteristics of innate immune cells and their associations with EBV infection post-haploHSCT are still unknown to date.
We recently compared the influences of different doses of antithymocyte globulin (ATG, 6 mg/kg vs 10 mg/kg in haploHSCT conditioning regimens) on the recovery of T lymphocytes. 15 We found that recoveries of a special T-cell subpopulation, CD4/CD8 double-negative T cells, on days 30, 60, 90 and 180 after haploHSCT were all significantly delayed in 31 recipients conditioned with 10 mg/kg ATG, compared with those in 29 recipients conditioned with 6 mg/kg ATG. Meanwhile, we observed an increased incidence of EBV reactivation in the 10 mg/kg ATG group. 15 Although correlation analysis suggested an interaction between CD4 − CD8 − T-cell reconstitution and EBV reactivation in this context, the conclusion need to be further confirmed. In addition, whether recovery of CD4 − CD8 − T cells is associated with other outcomes of haploHSCT remains unclear. In the present study, we are specifically interested in comparison of reconstitution of CD4/CD8 double-negative T cells between haploHSCT recipients with and without EBV reactivation. The correlation of this special T-cell subpopulation with haploHSCT outcomes will also be explored.
PATIENTS AND METHODS

Patients and study design
The aim of this study was to confirm the association between the recovery of CD4/CD8 double-negative T lymphocytes and occurrence of EBV reactivation in patients who underwent haploHSCT. A total of 1192 consecutive subjects received haploHSCT at Peking University Institute of Hematology from January 2011 to December 2014. As shown in Figure 1 , 1027 patients were diagnosed as hematological malignancy and received 10 mg/kg of ATG conditioning before transplantation. Among them, 155 recipients were identified with EBV reactivation and were further screened. We excluded 34 patients who died within 6 months after HSCT, 38 patients who did not consent to receive immunophenotyping analysis, and 19 patients for whom their immunophenotypes were technically undetectable at the first month after transplantation. Finally, 64 recipients with EBV reactivation (EBV+ group) were included in the present study. The control cohort (EBV − group) comprised 192 recipients testing negative for EBV DNA load, paired in a 3:1 ratio and age-and gender-matched to the EBV+ cohort. All patients were followed up for 1 year after haploHSCT.
The conditioning regimens including busulfan, cyclophosphamide and ATG (thymoglobulin; rabbit ATG, Imtix Sangstat, Lyon, France), and transplant procedures, GvHD prophylaxis (cyclosporine A and short-term methotrexate with mycophenolate mofetil) and treatment, and evaluations of acute GvHD were described previously. 16 The Ethics Committee of Peking University Institute of Hematology approved the study protocol. All recipients and their donors signed consent forms.
Diagnosis and treatment of EBV infection
All recipients and donors tested negative for EBV DNA in the peripheral blood before transplantation. Recipients were monitored weekly for EBV DNA load until day 100 after transplantation. From day 100 to day 180, recipients were monitored for EBV DNA load every 2 weeks. EBV monitoring was discontinued after 6 months post haploHSCT. Clinical features attributable to EBV infection were also monitored. Recipients with peripheral blood plasma EBV DNA load 41000 copies/mL at least once were diagnosed as EBV reactivation (EBV+), according to the criteria updated on European Conference on Infections in Leukemia 2015. EBV − cohort generally represents patients whose EBV DNA load was undetectable (o500 copies/mL) in peripheral blood. A few patients in this cohort occasionally had a low level of EBV DNA load (o1000 copies/mL).
In the present study, 30 of 64 (46.9%) patients with EBV-DNAemia accompanied by a fever and/or lymphadenopathy, in the absence of other etiologic factors and established diseases, were treated with rituximab (monoclonal anti-CD20 antibody, 375 mg/m 2 weekly) until clearance of EBV-DNAemia was achieved. Mean number of rituximab infusions was 3 (range: 1-4).
Immunophenotyping analysis
Immunophenotyping for T lymphocytes was performed with flow cytometry on day 30, 90 and 180 post haploHSCT. In brief, fresh peripheral blood cells were stained with fluorochrome-labeled antibodies against cluster of differentiation CD4/CD8/CD3 (Cat# 559770) and CD28 (Cat# 340298) purchased from Becton Dickinson (San Jose, CA, USA). Polychromatic flow cytometric analyses were performed on a custom high resolution LSRII (Becton Dickinson).
Statistical analysis
Statistical differences between the groups in age and recoveries of T-lymphocyte subpopulations at different time points were analyzed with the Mann-Whitney U-test. Differences between the two groups in gender, type of primary disease and incidences of acute GvHD and infections were analyzed with the χ 2 -test. Landmark study was performed to evaluate the correlation of double-negative T-cell recovery with the occurrence of EBV reactivation after haploHSCT. Cox regression multivariate analysis was conducted to evaluate if EBV reactivation and double-negative T-cell reconstitution remain independent variables to transplantation outcomes. Statistical significance was defined as P ⩽ 0.05, based on a two-tailed test. All calculations were carried out with SPSS 16.0 statistical software (SPSS Inc, Chicago, IL, USA). 
RESULTS
Characteristics of patients
The characteristics of patients in EBV+ and EBV-groups are summarized in Table 1 . Previous studies suggested that age of recipients and numbers of CD34 + cells in grafts could influence immune recovery. In the current study, recipients' ages and the counts of CD34 + cells in grafts were comparable between the groups. Meanwhile, no statistical differences in gender ratio and types of primary disease were found between the EBV+ and EBV-groups (Table 1 ). All included patients underwent the same procedures of donor priming (recombinant human granulocyte-colony stimulating factor), graft harvesting (peripheral blood progenitor cells and unmanipulated bone marrow), conditioning, and GvHD prophylaxis (as described in Materials and Methods). − T cells. On day 30 after haploHSCT, the median levels of all detected T-cell subsets were significantly lower in the EBV+ group than those in the EBV− group (P o0.001, Table 2 Table 2) . Landmark study was performed to further evaluate the causal relationship of CD4/CD8 double-negative T-cell (DNT) recovery with the occurrence of EBV reactivation after haploHSCT. The median DNT count for all patients was 7.7 (range: 0.1-246) cells/μL at day 30 after HSCT; therefore, the cohort was divided into two groups, those with lower (o 7.7 cells/μL) and higher (⩾7.7 cells/μL) DNT counts. As shown in Figure 2a , the cumulative incidence of EBV reactivation was increased significantly in the lower DNT group compared with the higher DNT group (P = 0.001). A similar result was observed when comparing the cumulative incidences of EBV reactivation between lower and higher day 90 DNT groups (P = 0.023, Figure 2b ). These observations indicated that hampered recovery of CD4 − CD8 − T cells correlated to the increased occurrence of EBV reactivation after haploHSCT.
Incidences of other infections and acute GvHD were comparable between the recipients with and without EBV reactivation after haploHSCT To evaluate if delayed recovery of CD4 − CD8 − T cells is specifically associated with EBV reactivation in the context of haploHSCT, occurrence of other infections attributed to CMV, bacteria and fungi was also compared. As shown in Table 3 , the incidences of CMV reactivation, bacteremia and invasive fungal infection were not significantly different between the EBV+ and EBV -groups (P40.1, respectively). Previous studies reported that development of acute GvHD was associated with the reconstitution of T lymphocytes after allogeneic HSCT. In the current study, incidences of acute GvHD were comparable between the EBV+ and EBV− groups (Table 4) . Further time-dependent covariate analysis found that the cumulative incidence of EBV reactivation was not correlated with CMV reactivation and acute GvHD status (Figures 3a and 3b, ) .
Recovery of CD4 − CD8 − T cells was correlated with TRM and relapse after haploHSCT Next, differences in the rates of relapse, transplant-related mortality (TRM) and overall survival between the EBV+ and EBV− groups were analyzed. We found that 17.2% of recipients in the EBV+ group relapsed within 1 year after haploHSCT, versus 6.8% in the EBV− group (P = 0.013, Table 4 ). In line with the previous reports, TRM rate of EBV+ recipients (20.3%) was significantly higher than that of the EBV− group (3.1%). Accordingly, 1-year survival rate was significantly decreased in EBV + group (70.3%) compared with the control cohort (93.2%). The reasons for death in the EBV+ cohort included relapse, GvHD, post-transplantation lymphoproliferative disorder, pulmonary infection, viral encephalitis and intracranial hemorrhage. Death due to pulmonary infection was observed more frequently in the EBV+ cohort compared with the EBV − cohorts (P o0.001, Table 4 ).
Considering that poor outcomes after HSCT could also be attributed to the weakened immune reconstitution, we further conducted multivariate analysis to evaluate if EBV reactivation and CD4/CD8 double-negative T-cell reconstitution remain independent variables to predict transplantation outcomes. As shown in Table 5 , EBV reactivation was an independent variable to predict both TRM (P = 0.002) and relapse (P = 0.004). When evaluating T-cell reconstitution, CD4 −
CD8
− T-cell numbers at days 90 and 180 were independent risk factors for TRM (P = 0.02) and relapse (P = 0.005), respectively.
Taken together, the present study confirmed that delayed recovery of CD4/CD8 double-negative T cells was correlated with the occurrence of EBV reactivation after haploHSCT. We also showed the significant correlations of the CD4 − CD8 − T-cell recovery with the poor transplantation outcomes.
DISCUSSION
Factors that influence the recovery of T lymphocytes after allogeneic HSCT, has been identified in the literature, include Abbreviations: GVHD = graft-versus-host disease; PTLD = post-transplantation lymphoproliferative disorder; TRM = transplant-related mortality.
a Numbers (ratio), unless indicated otherwise.
EBV reactivation and CD4
− CD8 − T cells after haploHSCT Z Bian et al age of recipient, immunosuppressive regimens (such as ATG, CsA), donor match, number of CD34 + cells in the graft, CMV reactivation and development of acute GvHD. 17, 18 In the present study, the dosage (10 mg/kg) and timing of ATG administration in conditioning regimens were identical for all the recipients involved. For every transplant recipient, the whole blood CsA concentration was monitored weekly for at least 6 months and the dosage was adjusted to maintain a blood trough concentration of 150-250 ng/mL. Therefore, the differential influences of ATG and CsA between the EBV+ and EBV − cohorts should have been minimized. Comparisons in other pre-and post-transplant factors were not significantly different between the two groups (Table 1) . These results excluded the relevant effects of other factors on the recovery of T lymphocytes, and enhanced the reliability of our finding that showed recovery of CD4/CD8 double-negative T cells correlated with EBV reactivation post-haploHSCT. CD4 − CD8 − T cells were proposed to originate in the thymus by escaping negative selection followed by migration in the periphery where they expand upon experiencing Ag. 19, 20 Previous studies described a regulatory role of CD4 − CD8 − T cells in reducing immune activation during inflammation and autoimmunity. 21, 22 Recently, a role for double-negative T cells in responses to viral infections is increasingly being recognized, especially in the setting of acute HIV infection. [23] [24] [25] [26] However, report on the association of CD4 − CD8 − T cells with EBV reactivation is scarce. Although the causal relationship need to be further investigated, results from time-dependent covariate and landmark study in the current work indicated that delayed recovery of this special T-cell subpopulation was significantly correlated with an increase of EBV reactivation in the context of haploHSCT. Thus, CD4
−
CD8
− T cell might be a potential target for future intervention strategies to control EBV reactivation.
Another concern is that delayed recovery of double-negative T cells may indicate the delayed immune recovery in general, not specific for EBV infection. Thus delayed immune recovery is associated with poorer outcome. Indeed, we found that recoveries of all detected T-cell subsets were hampered at the first month after haploHSCT. However, compared to the levels of total T cells and other T-cell subsets, only the CD4 −
− T-cell counts in EBV+ group were lower than the controls from day 30 to day 180 after transplantation. Multivariate analysis further indicated that double-negative T-cell numbers at days 90 and 180 were independent risk factors for TRM and relapse, respectively. On the other hand, the incidences of other infections attributed to CMV, bacteria and fungi were not significantly different between the cohorts with and without EBV reactivation. These observations suggest that delayed recovery of double-negative T cells is specific for EBV and not a general marker for a delayed immune recovery.
Notably, heterogeneity within in the CD4 − CD8 − T cells should not be ignored. Based on the expression of αβ or γδ T-cell receptors, or NK cell markers, several subpopulations of CD4 − CD8 − T cells have been identified, for example, TCR-γ/δ+ (γδ T) cells, TCR-α/β+ double-negative T (DN Treg) cells, NKT cells and other cells that are incompletely characterized. 23 As these cell subpopulations are not routinely monitored at our institute, we currently do not know if these cells are related to the occurrence of EBV reactivation and other complications after haploHSCT. A future prospective study will be performed to elucidate . CMV reactivation and acute GvHD status were not associated with the cumulative incidence of EBV reactivation after haploHSCT. Time-dependent covariate analysis for the correlation of CMV reactivation (a) and acute GvHD status (b) with the cumulative incidence of EBV reactivation after haploHSCT. 
− T cells was correlated with the poor outcomes of haploHSCT recipients. These results not only suggest a significant correlation of recovery of CD4/CD8 double-negative T cells with EBV infection, but also are under way to better recognize the reconstitution characteristics of this special T-cell subpopulation related to the serious complications of HSCT. Our findings could benefit the protection against EBV reactivation and the overall outcome of haploHSCT recipients.
